Cargando…
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230432/ https://www.ncbi.nlm.nih.gov/pubmed/36546422 http://dx.doi.org/10.3324/haematol.2022.281963 |
| _version_ | 1785051526600851456 |
|---|---|
| author | Pirosa, Maria Cristina Sassone, Marianna Kiesewetter, Barbara Guillermo, Armando Lopez Devizzi, Liliana Domènech, Eva Domingo Tucci, Alessandra Mannina, Donato Merli, Michele Salar, Antonio Visco, Carlo Esposito, Fabiana Bonomini, Luisella Zucca, Emanuele Ferreri, Andrés J. M. Raderer, Markus |
| author_facet | Pirosa, Maria Cristina Sassone, Marianna Kiesewetter, Barbara Guillermo, Armando Lopez Devizzi, Liliana Domènech, Eva Domingo Tucci, Alessandra Mannina, Donato Merli, Michele Salar, Antonio Visco, Carlo Esposito, Fabiana Bonomini, Luisella Zucca, Emanuele Ferreri, Andrés J. M. Raderer, Markus |
| author_sort | Pirosa, Maria Cristina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10230432 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102304322023-06-01 IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma Pirosa, Maria Cristina Sassone, Marianna Kiesewetter, Barbara Guillermo, Armando Lopez Devizzi, Liliana Domènech, Eva Domingo Tucci, Alessandra Mannina, Donato Merli, Michele Salar, Antonio Visco, Carlo Esposito, Fabiana Bonomini, Luisella Zucca, Emanuele Ferreri, Andrés J. M. Raderer, Markus Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-12-22 /pmc/articles/PMC10230432/ /pubmed/36546422 http://dx.doi.org/10.3324/haematol.2022.281963 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Pirosa, Maria Cristina Sassone, Marianna Kiesewetter, Barbara Guillermo, Armando Lopez Devizzi, Liliana Domènech, Eva Domingo Tucci, Alessandra Mannina, Donato Merli, Michele Salar, Antonio Visco, Carlo Esposito, Fabiana Bonomini, Luisella Zucca, Emanuele Ferreri, Andrés J. M. Raderer, Markus IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma |
| title | IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma |
| title_full | IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma |
| title_fullStr | IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma |
| title_full_unstemmed | IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma |
| title_short | IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma |
| title_sort | ielsg40/cleo phase ii trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230432/ https://www.ncbi.nlm.nih.gov/pubmed/36546422 http://dx.doi.org/10.3324/haematol.2022.281963 |
| work_keys_str_mv | AT pirosamariacristina ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT sassonemarianna ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT kiesewetterbarbara ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT guillermoarmandolopez ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT devizzililiana ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT domenechevadomingo ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT tuccialessandra ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT manninadonato ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT merlimichele ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT salarantonio ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT viscocarlo ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT espositofabiana ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT bonominiluisella ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT zuccaemanuele ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT ferreriandresjm ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma AT raderermarkus ielsg40cleophaseiitrialofclarithromycinandlenalidomideinrelapsedrefractoryextranodalmarginalzonelymphoma |